QuidelOrtho Corporation/$QDEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Ticker
$QDEL
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
6,600
ISIN
US2197981051
Website
QDEL Metrics
BasicAdvanced
$2B
-
-$5.33
0.13
-
Price and volume
Market cap
$2B
Beta
0.13
52-week high
$49.45
52-week low
$23.77
Average daily volume
1.5M
Financial strength
Current ratio
1.201
Quick ratio
0.54
Long term debt to equity
75.711
Total debt to equity
88.85
Interest coverage (TTM)
0.61%
Profitability
EBITDA (TTM)
560.7
Gross margin (TTM)
46.94%
Net profit margin (TTM)
-12.97%
Operating margin (TTM)
4.26%
Effective tax rate (TTM)
-5.07%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
1.12%
Return on equity (TTM)
-11.38%
Valuation
Price to revenue (TTM)
0.726
Price to book
0.67
Price to tangible book (TTM)
-5.41
Price to free cash flow (TTM)
-55.887
Free cash flow yield (TTM)
-1.79%
Free cash flow per share (TTM)
-53.30%
Growth
Revenue change (TTM)
-3.42%
Earnings per share change (TTM)
-79.79%
3-year revenue growth (CAGR)
5.94%
10-year revenue growth (CAGR)
30.22%
3-year earnings per share growth (CAGR)
-39.10%
10-year earnings per share growth (CAGR)
57.72%
What the Analysts think about QDEL
Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Bulls say / Bears say
Jefferies upgraded QuidelOrtho's stock from Hold to Buy on May 8, 2025, with an average one-year price target suggesting a 49.28% upside. (nasdaq.com)
QuidelOrtho's strong product portfolio, including the recent addition of the ARK Fentanyl II Assay and FDA clearance for its QuickVue COVID-19 test, positions the company well for future growth. (nasdaq.com)
The company's commitment to research and development, focusing on next-generation platforms and assays, indicates a strategic emphasis on long-term growth. (nasdaq.com)
QuidelOrtho reported a 14% year-over-year revenue decline in Q4 2023, with respiratory revenues dropping by approximately 49%, leading to analyst downgrades. (globenewswire.com)
The Carlyle Group sold 8,260,183 shares of QuidelOrtho stock in November 2024, potentially signaling reduced confidence from a major shareholder. (etfdailynews.com)
A securities class action lawsuit was filed against QuidelOrtho in June 2024, alleging misrepresentation of COVID-19 test sales and potential delays in product launches. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
QDEL Financial Performance
Revenues and expenses
QDEL Earnings Performance
Company profitability
QDEL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QuidelOrtho Corporation stock?
QuidelOrtho Corporation (QDEL) has a market cap of $2B as of July 02, 2025.
What is the P/E ratio for QuidelOrtho Corporation stock?
The price to earnings (P/E) ratio for QuidelOrtho Corporation (QDEL) stock is 0 as of July 02, 2025.
Does QuidelOrtho Corporation stock pay dividends?
No, QuidelOrtho Corporation (QDEL) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next QuidelOrtho Corporation dividend payment date?
QuidelOrtho Corporation (QDEL) stock does not pay dividends to its shareholders.
What is the beta indicator for QuidelOrtho Corporation?
QuidelOrtho Corporation (QDEL) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.